Цель данной аналитической записки – предоставить краткое изложение информации и соображений,
касающихся принятия оптимальных мер в отношении гриппа во время па
...
демии COVID-19. В документе
рассматриваются первостепенные вопросы, с которыми могут столкнуться директивные органы, в том числе
вероятность одновременной циркуляции вирусов гриппа и SARS-CoV-2, дифференциальная диагностика
гриппа и COVID-19 у пациентов, а также планирование мероприятий по профилактике и борьбе с гриппом.
Кроме того, в документе содержатся ссылки на подробные технические рекомендации и другие ресурсы,
посвященные мерам, которые в одинаковой степени значимы как для борьбы с гриппом, так и COVID-19, в том
числе мониторинг ситуации, профилактика сезонного гриппа, снижение частоты случаев тяжелых осложнений
и летального исхода, охрана здоровья отдельных групп населения, а также взаимодействие и привлечение к
участию общественности. Influenza preparedness during the COVID-19 pandemic
more
Presentations and agenda of the meeting held to update industry on the COVAX Facility and Gavi’s support for cold chain equipment (CCE) for COVID-19 vaccines.
Explainer for countries based on commonly asked questions
12 November 2020
This document aims to explain how COVAX vaccines will be allocated amongst participants.
MEDBOX Issue Brief no.9 ,1 Febr. 2021
The Country Readiness and Delivery(CRD) workstream which is part of the ACT Accelerator and is included in the SPRP– has developed a toolbox with guidance, tools and training.
This catalogue provides tools and information resources to support EU/EEA countries in addressing the challenging issue of vaccine hesitancy. The catalogue provides examples of practices that can serve as a resource for other countries. The project was developed in the context of ECDC’s support fo
...
r EU/EEA Member States in prevention and control of vaccine-preventable diseases, including effective communication to promote immunisation.
more
The authors state that researchers, governments and global agencies should proceed with particular care in the evaluation of candidate SARS-CoV-2 vaccines in LMICs, with effective communication to build trust and avoid generation of vaccine hesitancy. Vaccine efficacy is often highly variable betwee
...
n high-resource and low-resource settings
Archives of Disease in Childhood, vol.106 Issue 2
more
How far apart should the doses of vaccines be? What if I miss my second dose? Can I get two doses from two different manufacturers? How was safety of vaccines ensured? WHO’s Chief Scientist, Dr Soumya Swaminathan explains in Science in 5.
Vaccines 2021, 9(2), 160; https://doi.org/10.3390/vaccines9020160
Social Media + SocietyJuly-September 2020: 1 –4
Обновленная версия Декабрь 2020 г.
This global guidance provided the framework for over 100 countries to develop their NDVPs. This updated (second) version supersedes the previous version published in 16 November 2020. New information has been added on the following areas:
the COVID-19 Partners Platform;
the use of COVID
...
-19 simulation exercises to test deployment strategies;
the indemnity agreement and no-fault compensation programme for vaccines secured through the COVAX Facility in the Advance Market Commitment (AMC) eligible economies;
the availability and use of the WHO-UNICEF COVID-19 Vaccine Introduction and deployment Costing (CVIC) tool;
the COVAX Facility’s humanitarian buffer that enables allocation of vaccine to cover high-risk populations in humanitarian settings;
recommendations for vaccination of pregnant and lactating women;
supplementary information on infection prevention and control (IPC) measures to be used to deliver COVID-19 vaccines safely;
the WHO licensed COVID-19 vaccines product-specific information;
use of geospatial data and digital micro plans for equitable access and delivery of COVID-19 vaccines;
lessons learned from the development of NDVPs and early experiences in COVID-19 vaccine deployment in countries; and
updated additional resources at the end of each chapter.
more
A WHO-UNICEF joint statement encouraging greater health commodity supply chain integration for temperature-sensitive pharmaceuticals where appropriate, 19 November 2020
This guide is intended to support national governments developing their national deployment and vaccination plans (NDVPs) for COVID-19 vaccines by outlining the roles, needs and opportunities for community health workers (CHWs) to contribute. This note builds on and is structured to align with the G
...
uidance on developing a national deployment and vaccination plan for COVID-19 vaccines. By providing CHW-relevant considerations for the VIRAT Tool, this document aims to support national governments in developing robust NDVPs for introducing COVID-19 vaccine(s) that leverage all the community-based deployment, implementation and monitoring tools at their disposal.
more
Interim guidanceAnnex to: Policy considerations for implementing a risk-based approach to international travel in the context of COVID-19, 2 July 2021
Le Bénin en registre chaque année environ 1500 décès maternels et plus de 12 000 décès de nouveau-nés. Face à cette situation, il estélaboré le plan opérationnel de réduction de la mortalité maternelle et néonatale 2018 –2022. Il s’agit du document par lequel le Minist
...
re de la Santé fixe les objectifs, détermine les stratégies permettant de les atteindre, ainsi que les interventions cliniques, managériales, politiques, législatives et autres requises pour infléchir les indicateurs de mortalité maternelle et néonatale. Le document comporte six (6) parties:-la méthodologie d’élaboration;-l’analyse des progrès en matière de réduction de la mortalité maternelle et néonatale; -le cadre stratégique;-le cadre de mise en œuvre;-les plans d’actions budgétisés par niveau de la pyramide sanitaire; -le cadre de coordination, et de suivi / évaluation.
more